News for BridgeBio Pharma Inc Stock (BBIO)

BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

GlobeNewsWire • 02/22/24

Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for

Zacks Investment Research • 02/15/24

BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan

GlobeNewsWire • 02/07/24

BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

GlobeNewsWire • 02/05/24

BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

GlobeNewsWire • 02/02/24

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

PRNewsWire • 01/30/24

3 Groundbreaking Biotech Stocks to Invest in Now

InvestorPlace • 01/29/24

BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines

GlobeNewsWire • 01/18/24

BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck

Seeking Alpha • 01/11/24

BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine

GlobeNewsWire • 01/10/24

BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner

Seeking Alpha • 01/08/24

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

GlobeNewsWire • 01/03/24

BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)

GlobeNewsWire • 01/03/24

2 Biotechs That Could Get Bought Out in 2024

The Motley Fool • 01/03/24

3 Russell 2000 Stocks That Are About to Get Absolutely Crushed

InvestorPlace • 12/18/23

BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

GlobeNewsWire • 12/13/23

BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

GlobeNewsWire • 12/05/23

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

GlobeNewsWire • 11/12/23

BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023

GlobeNewsWire • 11/09/23

BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update

GlobeNewsWire • 11/02/23

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research • 10/26/23

Why BridgeBio Pharma Was a Healthy Stock Today

The Motley Fool • 10/24/23

BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire • 10/11/23

BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)

GlobeNewsWire • 10/10/23

BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

GlobeNewsWire • 10/09/23